

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

VOLUNTARY ANNOUNCEMENT
SHAREHOLDING INCREASE PLAN BY THE CONTROLLING
SHAREHOLDER OF JIANGZHONG PHARMACEUTICAL

This is a voluntary announcement made by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”).

Jiangzhong Pharmaceutical Co., Ltd. (江中藥業股份有限公司) (“**Jiangzhong Pharmaceutical**”) is a company incorporated in the People’s Republic of China. The shares of Jiangzhong Pharmaceutical are listed on the Shanghai Stock Exchange. As of the date of this announcement, Jiangzhong Pharmaceutical is owned as to approximately 43.09% equity interest by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) through its non-wholly owned subsidiary, China Resources Jiangzhong Pharmaceutical Group Co., Ltd. (華潤江中製藥集團有限責任公司) (“**CR Jiangzhong**”). The Group controls an effective interest of approximately 26.09% of Jiangzhong Pharmaceutical, which is accounted for as a subsidiary of the Company.

Our company acknowledges that, on 21 October 2024, Jianzhong Pharmaceutical received a notice from its controlling shareholder, CR Jiangzhong, indicating that CR Jiangzhong intends to increase its shareholdings in Jianzhong Pharmaceutical within 12 months from the date of this announcement through methods permitted by the Shanghai Stock Exchange trading system (including but not limited to, centralized bidding and bulk transactions) (the **“Shareholding Increase Plan”**). The total amount of the shareholding to be increased will be no less than RMB60 million (inclusive) and no more than RMB120 million (inclusive). The details of the Shareholding Increase Plan are as follows:

1. Purpose of the Shareholding Increase Plan: With confidence in the future development prospects of Jianzhong Pharmaceutical and recognition of its medium and long-term investment value, and to increase investor confidence, CR Jiangzhong intends to implement the Shareholding Increase Plan.
2. Type of shares and method of the Shareholding Increase Plan: CR Jiangzhong intends to increase its holdings of the A shares of Jianzhong Pharmaceutical through methods permitted by the Shanghai Stock Exchange (including but not limited to, centralized bidding transactions, bulk transactions).
3. Total amount of the shareholding to be increased: The total amount of the shareholding to be increased will be no less than RMB60 million (inclusive) and no more than RMB120 million (inclusive).
4. Price of the shareholding to be increased: There is no pre-determined price range for the Shareholding Increase Plan. The Shareholding Increase Plan will be implemented based on the value judgment of Jianzhong Pharmaceutical’s stock and market fluctuations in the secondary market.
5. Implementation period of the Shareholding Increase Plan: Considering factors including market fluctuations and fund arrangements, the Shareholding Increase Plan will be executed within 12 months from the date of this announcement based on the overall trends of the capital market. If Jianzhong Pharmaceutical’s stock is suspended for trading for more than 10 consecutive trading days due to major events during the implementation period of the Shareholding Increase Plan, the Shareholding Increase Plan will be postponed and implemented after Jianzhong Pharmaceutical’s stock resumes trading.

6. Funding arrangement for the Shareholding Increase Plan: CR Jiangzhong intends to use its own funds or self-raised funds to increase its holdings of Jiangzhong Pharmaceutical's A shares.
7. Undertakings by the entity to increase shareholdings: CR Jiangzhong undertakes not to reduce its holdings of Jiangzhong Pharmaceutical's shares during the implementation period of the Shareholding Increase Plan and within the statutory period.

This announcement is made by the Company on a voluntary basis to provide information to its shareholders and potential investors. Shareholders and potential investors of the Company are reminded to exercise caution in dealing with the securities of the Company.

For ease of reference, the names of the PRC established companies or entities have been included in this announcement in both the Chinese and English languages, and in the event of any inconsistency, the Chinese versions shall prevail.

By Order of the Board of Directors
China Resources Pharmaceutical Group Limited
Bai Xiaosong
Chairman

PRC, 21 October 2024

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.